The global hypoventilation management market is expected to reach a valuation of USD 7.1 billion in 2023, and is projected to reach USD 11.9 billion by 2033, trailing a CAGR of 5.3% during the forecast period.
Growing healthcare expenditure, advancement in the treatment options, unhealthy lifestyle, rising incidence of obesity, growing initiatives by government and private organisations to spread awareness towards health and lack of exercise in the daily routine are the factors that will expand hypoventilation syndrome treatment market.
Also, increase in the research and development activities and ongoing clinical trials will provide beneficial opportunities for hypoventilation syndrome treatment market in the forecast period of 2023-2033.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 7.1 billion |
| Anticipated Forecast Value (2033) | USD 11.9 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 5.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for hypoventilation management was worth USD 6 billion in 2018, while growing at a CAGR of 3.42% during the historical period. The growth of hypoventilation drug market is being fuelled by increasing demand for medications to treat symptoms such as shortness of breath, coughing, mucus production, and wheezing, as well as the convenience and ease of using these treatments and therapies in the comfort of one's own home. A better understanding of respiratory illnesses, their treatments, and the necessary precautions has an additional effect on the market for medications used to treat hypoventilation diseases.
The value of the market for treatments for hypoventilation disease is boosted by the rising funding of research and development and drug production by governments and pharmaceutical corporations. Asthma and Chronic obstructive pulmonary diseases are on the rise, and the senior population is also on the rise, thus these are three main factors pushing the industry forward.
The global market value for Hypoventilation management is poised to increase significantly as a result of the government approving medicines and biosimilars. This market is booming thanks to improvements in healthcare infrastructure, shifting consumer preferences, and increasing disposable income. Considering the above-mentioned factors, the market of hypoventilation is expected to be worth USD 11.9 billion with a CAGR of 5.3% by end of the forecast period.
Advancements in medical technology propelling market growth
Increasing prevalence of sleep related hypoventilation and growing healthcare expenditure are the major factors driving market growth. Furthermore, advancement in the medical technology, rising government funding and growing initiatives by public and private organisations to spread awareness about the disease and its preventive options are the factors that will expand hypoventilation treatment market.
Other factors including alcohol abuse, growing incidences of obesity, asthma and hypothyroidism and utilization of medication involving opiates and benzodiazepines will also help in propelling the market growth.
Principal Consultant
High cost of treatment restraining industry expansion
High cost of treatment and complications associated with various hypoventilation syndrome such as obesity related hypoventilation, sleep related hypoventilation, Chronic obstructive pulmonary disease, are the factors that will challenge market growth and will further restrain the hypoventilation syndrome treatment market in the forecast period.
North America expected to dominate the market with the maximum share
North America accounted for the largest share of around 41% of the global market in 2022. The market in the region is projected to grow at a CAGR of 4.39% from 2023 to 2033. This can be ascribed to the highly structured healthcare industry and the availability of well-defined reimbursement policies from private and public health insurance firms.
Furthermore, growth in research & development activities to provide advanced and efficient products, and the presence of key players are driving the hypoventilation treatment market size in this region.
The market in South-Asia expected to witness fastest CAGR
The market in South-Asia is expected to grow at the fastest CAGR of 5.5% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions.
Therefore, South Asia offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the hypoventilation treatment market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Chronic obstructive pulmonary disease driving growth with maximum share
Chronic obstructive pulmonary disease is projected to dominate the market with a market share of around 55% by end of the forecast period. This segment is estimated to reflect a CAGR of 6% during the forecast period. Adoption of combination therapies including LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs are boosting the segment’s growth. Adoption of these therapies is increasing, as it is more effective than the separate use of bronchodilators and corticosteroids.
Growth in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is anticipated to fuel the growth of chronic obstructive pulmonary disease treatment. Moreover, combination therapy is more effective than monotherapy for improving symptoms and quality of life. Thus, boosting the segment’s growth.
Hospitals will lead the segment with the maximum share
This segment is expected to lead the market with a market share of 71% by end of the forecast period. Rising investments in healthcare infrastructure, easy availability of diagnostic machines, and easy access to skilled professionals are some of the factors driving the growth of this segment. Furthermore, hospitals are convenient for using combination therapies in the treatment of hypoventilation disorder which also boosts this segment’s growth.
The global Hypoventilation management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 7.1 billion |
| Market Value in 2033 | USD 11.9 billion |
| Growth Rate | CAGR of 5.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Disease Type, Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, UAE, South Africa, Israel |
| Key Companies Profiled | Accord Healthcare Limited; Avet Pharmaceuticals Inc.; Nostrum Laboratories Inc.; Lannett Co Inc.; Strides Pharma Science Limited; X Gen Pharmaceuticals Inc.; ResMed; Koninklijke Philips NV; Hikma Pharmaceuticals; Lincare Holdings |
| Customization | Available Upon Request |
FMI projects the global Hypoventilation management market to expand at a 5.3% value CAGR by 2033.
The global Hypoventilation management market is expected to garner a market value of USD 11.9 billion by 2033.
FMI has projected North America to be one of the most lucrative regions for Hypoventilation management market.
South Asia region is anticipated to grow fastest during the forecast period.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 5.1. Chronic Obstructive Pulmonary Disease 5.2. Obesity Hypoventilation Syndrome (OHS) 5.3. Central Alveolar Hypoventilation 5.4. Neuromuscular Disorders 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Oxygen Therapy 6.2. Non-invasive Mechanical Ventilation 6.3. Drug Therapy 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 7.1. Hospitals 7.2. Specialty Clinics 7.3. Home Care 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Accord Healthcare Limited 18.2. Avet Pharmaceuticals Inc 18.3. Nostrum Laboratories Inc 18.4. Lannett Co Inc 18.5. Strides Pharma Science Limited 18.6. X Gen Pharmaceuticals Inc 18.7. ResMed 18.8. Koninklijke Philips NV 18.9. Hikma Pharmaceuticals 18.10. Lincare Holdings 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Hypoventilation Management Market
